For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

Click here to access the investor kit.

Amgen - Recent Press Releases
11/18/14Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C LevelsPrinter Friendly Version
11/14/14Amgen To Present At The Jefferies Global Healthcare ConferencePrinter Friendly Version
11/12/14Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific SessionsPrinter Friendly Version
11/12/14Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication EvolocumabPrinter Friendly Version
11/12/14The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions WorldwidePrinter Friendly Version
11/11/14Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque PsoriasisPrinter Friendly Version
11/10/14FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication EvolocumabPrinter Friendly Version
11/06/14Amgen To Present At The Credit Suisse Annual Healthcare ConferencePrinter Friendly Version
11/06/14Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014Printer Friendly Version
11/04/14Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian CancerPrinter Friendly Version